Last reviewed · How we verify
Bisoprolol Oral Tablet
At a glance
| Generic name | Bisoprolol Oral Tablet |
|---|---|
| Also known as | Betablocker, Bisoprolol hemifumarate |
| Sponsor | Vastra Gotaland Region |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- STunning in Acute Myocardial Infarction - BAS (PHASE4)
- Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension. (PHASE3)
- Preventing Adverse Cardiac Events in COPD (PHASE3)
- Exercise as an Immune Adjuvant for Allogeneic Cell Therapies (EARLY_PHASE1)
- Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART) (PHASE4)
- Determination of Drug Levels for Pharmacotherapy of Heart Failure (PHASE4)
- Concor® Bioequivalence Study in Chinese Participants (Darmstadt-Nantong) (PHASE1)
- Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bisoprolol Oral Tablet CI brief — competitive landscape report
- Bisoprolol Oral Tablet updates RSS · CI watch RSS
- Vastra Gotaland Region portfolio CI